475 related articles for article (PubMed ID: 33087494)
1. Neurofilament Light Chain as a Biomarker of Hereditary Transthyretin-Mediated Amyloidosis.
Ticau S; Sridharan GV; Tsour S; Cantley WL; Chan A; Gilbert JA; Erbe D; Aldinc E; Reilly MM; Adams D; Polydefkis M; Fitzgerald K; Vaishnaw A; Nioi P
Neurology; 2021 Jan; 96(3):e412-e422. PubMed ID: 33087494
[TBL] [Abstract][Full Text] [Related]
2. Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study.
Ticau S; Aldinc E; Polydefkis M; Adams D; Coelho T; Ueda M; Hale C; Vest J; Nioi P;
Amyloid; 2024 Mar; 31(1):1-11. PubMed ID: 37469249
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
4. Serum neurofilament light chain in hereditary transthyretin amyloidosis: validation in real-life practice.
Carroll AS; Razvi Y; O'Donnell L; Veleva E; Heslegrave A; Zetterberg H; Vucic S; Kiernan MC; Rossor AM; Gillmore JD; Reilly MM
Amyloid; 2024 Jun; 31(2):95-104. PubMed ID: 38348665
[TBL] [Abstract][Full Text] [Related]
5. Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis.
Zhang X; Goel V; Attarwala H; Sweetser MT; Clausen VA; Robbie GJ
J Clin Pharmacol; 2020 Jan; 60(1):37-49. PubMed ID: 31322739
[TBL] [Abstract][Full Text] [Related]
6. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
[TBL] [Abstract][Full Text] [Related]
7. Association of Patisiran, an RNA Interference Therapeutic, With Regional Left Ventricular Myocardial Strain in Hereditary Transthyretin Amyloidosis: The APOLLO Study.
Minamisawa M; Claggett B; Adams D; Kristen AV; Merlini G; Slama MS; Dispenzieri A; Shah AM; Falk RH; Karsten V; Sweetser MT; Chen J; Riese R; Vest J; Solomon SD
JAMA Cardiol; 2019 May; 4(5):466-472. PubMed ID: 30878017
[TBL] [Abstract][Full Text] [Related]
8. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study.
Adams D; Polydefkis M; González-Duarte A; Wixner J; Kristen AV; Schmidt HH; Berk JL; Losada López IA; Dispenzieri A; Quan D; Conceição IM; Slama MS; Gillmore JD; Kyriakides T; Ajroud-Driss S; Waddington-Cruz M; Mezei MM; Planté-Bordeneuve V; Attarian S; Mauricio E; Brannagan TH; Ueda M; Aldinc E; Wang JJ; White MT; Vest J; Berber E; Sweetser MT; Coelho T;
Lancet Neurol; 2021 Jan; 20(1):49-59. PubMed ID: 33212063
[TBL] [Abstract][Full Text] [Related]
9. Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis.
Louwsma J; Brunger AF; Bijzet J; Kroesen BJ; Roeloffzen WWH; Bischof A; Kuhle J; Drost G; Lange F; Kuks JBM; Gans ROB; Hazenberg BPC; Nienhuis HLA
Amyloid; 2021 Mar; 28(1):50-55. PubMed ID: 32883119
[TBL] [Abstract][Full Text] [Related]
10. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
[TBL] [Abstract][Full Text] [Related]
11. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
[TBL] [Abstract][Full Text] [Related]
12. An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Planté-Bordeneuve V; Lin H; Gollob J; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
Expert Opin Pharmacother; 2019 Mar; 20(4):473-481. PubMed ID: 30489166
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
Quan D; Obici L; Berk JL; Ando Y; Aldinc E; White MT; Adams D
Amyloid; 2023 Mar; 30(1):49-58. PubMed ID: 36120830
[TBL] [Abstract][Full Text] [Related]
14. Indirect treatment comparison of the efficacy of patisiran and inotersen for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Gorevic P; Franklin J; Chen J; Sajeev G; Wang JCH; Lin H
Expert Opin Pharmacother; 2021 Jan; 22(1):121-129. PubMed ID: 32892660
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of axonal damage to favor early diagnosis in variant transthyretin amyloidosis (A-ATTRv).
González-Moreno J; Gragera-Martínez Á; Rodríguez A; Borrachero-Garro C; García-Garrido S; Barceló C; Manovel-Sánchez A; Ribot-Sansó MA; Ibargüen-González L; Gomila R; Muñoz-Beamud F; Losada-López I; Cisneros-Barroso E
Sci Rep; 2024 Jan; 14(1):581. PubMed ID: 38182630
[TBL] [Abstract][Full Text] [Related]
16. Quality of life outcomes in APOLLO, the phase 3 trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
Obici L; Berk JL; González-Duarte A; Coelho T; Gillmore J; Schmidt HH; Schilling M; Yamashita T; Labeyrie C; Brannagan TH; Ajroud-Driss S; Gorevic P; Kristen AV; Franklin J; Chen J; Sweetser MT; Wang JJ; Adams D
Amyloid; 2020 Sep; 27(3):153-162. PubMed ID: 32131641
[No Abstract] [Full Text] [Related]
17. Neurofilament light chain as a disease severity biomarker in ATTRv: data from a single-centre experience.
Luigetti M; Di Paolantonio A; Guglielmino V; Romano A; Rossi S; Sabino A; Servidei S; Sabatelli M; Primiano G
Neurol Sci; 2022 Apr; 43(4):2845-2848. PubMed ID: 35094171
[TBL] [Abstract][Full Text] [Related]
18. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
[TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
20. Patisiran treatment in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy after liver transplantation.
Schmidt HH; Wixner J; Planté-Bordeneuve V; Muñoz-Beamud F; Lladó L; Gillmore JD; Mazzeo A; Li X; Arum S; Jay PY; Adams D;
Am J Transplant; 2022 Jun; 22(6):1646-1657. PubMed ID: 35213769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
